Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Research article

Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score

Authors: Z. Bakos, N. C. Chatterjee, C. Reitan, J. P. Singh, R. Borgquist

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

Cardiac resynchronization therapy (CRT) is an established therapy for appropriately selected patients with heart failure. Response to CRT has been heterogeneously defined using both clinical and echocardiographic measures, with poor correlation between the two.

Methods

The study cohort was comprised of 202 CRT-treated patients and CRT response was defined at 6 months post-implant. Echocardiographic response (E+) was defined as a reduction in LVESV ≥ 15%, clinical response as an improvement of ≥ 1 NYHA class (C+), and biomarker response as a ≥ 25% reduction in NT-proBNP(B+). The association of response measures (E+, B+, C+; response score range 0–3) and clinical endpoints at 3 years was assessed in landmarked Cox models.

Results

Echo and clinical responders demonstrated greater declines in NT-proBNP than non-responders (median [E+/B+]: -52%, [E+]: -27%, [C+]: -39% and [E-/C-]: -13%; p = 0.01 for trend). Biomarker (HR 0.43 [95% CI: 0.22–0.86], p = 0.02) and clinical (HR 0.40 [0.23–0.70] p = 0.001) response were associated with a significantly reduced risk of the primary endpoint. When integrating each response measure into a composite score, each 1 point increase was associated with a 31% decreased risk for a composite endpoint of mortality, LVAD, transplant and HF hospitalization (HR 0.69 [95% CI: 0.50–0.96], p = 0.03), and a 52% decreased risk of all-cause mortality (HR 0.48 [95% CI: 0.26–0.89], p = 0.02).

Conclusion

Serial changes in NT-proBNP are associated with clinical outcomes following CRT implant. Integration of biomarker, clinical, and echocardiographic response may discriminate CRT responders versus non-responders in a clinically meaningful way, and with higher accuracy.

Trial registration

The cohort was combined from study NCT01949246 and the study based on local review board approval 2011/550 in Lund, Sweden.
Appendix
Available only for authorised users
Literature
1.
Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.CrossRefPubMed
2.
Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.CrossRefPubMed
3.
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.CrossRefPubMed
4.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.CrossRefPubMed
5.
Gorcsan J 3rd. Finding pieces of the puzzle of nonresponse to cardiac resynchronization therapy. Circulation. 2011;123(1):10–2.CrossRefPubMed
6.
Ng CY, Heist EK. Cardiac Resynchronization Therapy: Maximizing the Response to Biventricular Pacing. Cardiol Rev. 2017;25(1):6–11. Review.
7.
Boerrigter G, Costello-Boerrigter LC, Abraham WT, St. John Sutton MG, Heublein DM, Kruger KM, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail. 2008;14:539–46.CrossRefPubMedPubMedCentral
8.
Venkateswaran RV, Freeman C, Chatterjee N, Kandala J, Orencole M, Vegh EM, et al. Anemia and its association with clinical outcome in heart failure patients undergoing cardiac resynchronization therapy. J Interv Card Electrophysiol. 2015;44(3):297–304.CrossRefPubMed
9.
Sardu C, Santamaria M, Funaro S, Sacra C, Barbieri M, Paolisso P, et al. Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome. Medicine (Baltimore). 2017;96(14):e6558.CrossRef
10.
Sardu C, Barbieri M, Santamaria M, Giordano V, Sacra C, Paolisso P, et al. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovasc Diabetol. 2017;16(1):75.CrossRefPubMedPubMedCentral
11.
Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53(9):765–73.CrossRefPubMed
12.
Altman RK, Parks KA, Schlett CL, Orencole M, Park MY, Truong QA, et al. Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes. Eur Heart J. 2012;33(17):2181–8.CrossRefPubMedPubMedCentral
13.
Boidol J, Sredniawa B, Kowalski O, Szulik M, Mazurek M, Sokal A, et al. Many response criteria are poor predictors of outcomes after cardiac resynchronization therapy: validation using data from the randomized trial. Europace. 2013;15(6):835–44.CrossRefPubMed
14.
Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation. 2010;121(18):1985–91.CrossRefPubMedPubMedCentral
15.
Brenyo A, Barsheshet A, Rao M, Huang DT, Zareba W, McNitt S, et al. Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure. Circ Heart Fail. 2013;6(5):998–1004.CrossRefPubMed
16.
Delgado RM, Palanichamy N, Radovancevic R, Vrtovec B, Radovancevic B. Brain natriuretic peptide levels and response to cardiac resynchronization therapy in heart failure patients. Congest Heart Fail. 2006;12(5):250–3.CrossRefPubMed
17.
Sardu C, Marfella R, Santulli G, Paolisso G. Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics. 2014;15(8):1159–68.CrossRefPubMed
18.
TheTask Force on cardiac p, resynchronization therapy of the European Society of Cardiology . Developed in collaboration with the European Heart Rhythm A, Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) 2014. 2013;67(1):58.
19.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and Antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117(21):e350–408.CrossRefPubMed
20.
Doltra A, Bijnens B, Tolosana JM, Borras R, Khatib M, Penela D, et al. Mechanical abnormalities detected with conventional echocardiography are associated with response and midterm survival in CRT. JACC Cardiovasc Imaging. 2014;7(10):969–79.CrossRefPubMed
21.
Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2012;60(17):1647–55.CrossRefPubMedPubMedCentral
22.
Biton Y, Zareba W, Goldenberg I, Klein H, McNitt S, Polonsky B, et al. Sex differences in long-term outcomes with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. J Am Heart Assoc. 2015;4(7)
23.
Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51(3):288–96.CrossRefPubMed
24.
Zhang Q, Zhou Y, Yu CM. Incidence, definition, diagnosis, and management of the cardiac resynchronization therapy nonresponder. Curr Opin Cardiol. 2015;30(1):40–9.CrossRefPubMed
25.
Bordachar P, Eschalier R, Lumens J, Ploux S. Optimal strategies on avoiding CRT nonresponse. Curr Treat Options Cardiovasc Med. 2014;16(5):299.CrossRefPubMed
26.
Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation. 2010;122(10):985–92.CrossRefPubMed
27.
Ge Y, Ruwald AC, Kutyifa V, McNitt S, Polonsky S, Klein H, et al. A metric for evaluating the cardiac response to resynchronization therapy. Am J Cardiol. 2014;113(8):1371–7.CrossRefPubMed
28.
St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120(19):1858–65.CrossRefPubMed
29.
Gold MR, Daubert C, Abraham WT, Ghio S, St John Sutton M, Hudnall JH, et al. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2014;
30.
Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses remodeling in systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34(33):2592–9.CrossRefPubMed
31.
Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7(2):176–82.CrossRefPubMed
32.
Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation. 2003;108(21):2596–603.CrossRefPubMed
33.
Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289(20):2685–94.CrossRefPubMed
34.
Reitan C, Bakos Z, Platonov PG, Hoijer CJ, Brandt J, Wang L, et al. Patient-assessed short-term positive response to cardiac resynchronization therapy is an independent predictor of long-term mortality. Europace. 2014;16(11):1603–9.CrossRefPubMed
35.
Oremus M, Don-Wauchope A, McKelvie R, Santaguida PL, Hill S, Balion C, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19(4):471–505.CrossRefPubMed
36.
Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev. 2014;19(4):453–70.CrossRefPubMed
37.
Shalaby AA, Abraham WT, Fonarow GC, Bersohn MM, Gorcsan J 3rd, Lee LY, et al. Association of BNP and troponin levels with outcome among cardiac resynchronization therapy recipients. Pacing Clin Electrophysiol. 2015;38(5):581–90.CrossRefPubMedPubMedCentral
38.
Berger R, Shankar A, Fruhwald F, Fahrleitner-Pammer A, Freemantle N, Tavazzi L, et al. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. Eur Heart J. 2009;30(17):2109–16.CrossRefPubMed
39.
Brouwers C, Versteeg H, Meine M, Heijnen CJ, Kavelaars AM, Pedersen SS, et al. Association between brain natriuretic peptide, markers of inflammation and the objective and subjective response to cardiac resynchronization therapy. Brain Behav Immun. 2014;40:211–8.CrossRefPubMed
40.
Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J. 2007;28(13):1592–7.CrossRefPubMed
41.
Braun MU, Rauwolf T, Zerm T, Schulze M, Schnabel A, Strasser RH. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. Heart. 2005;91(5):601–5.CrossRefPubMedPubMedCentral
42.
Seifert M, Schlegl M, Hoersch W, Fleck E, Doelger A, Stockburger M, et al. Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. Int J Cardiol. 2007;121(1):68–73.CrossRefPubMed
43.
Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, Karasova L, et al. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail. 2006;8(8):832–40.CrossRefPubMed
44.
Pitzalis MV, Iacoviello M, Di Serio F, Romito R, Guida P, De Tommasi E, et al. Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy. Eur J Heart Fail. 2006;8(5):509–14.CrossRefPubMed
45.
Sardu C, Marfella R, Santulli G. Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people. J Cardiovasc Transl Res. 2014;7(3):362–8.CrossRefPubMed
46.
Min X, Meine M, Baker JH 2nd, Pires LA, Turk KT, Horn EM, et al. Estimation of the optimal VV delay by an IEGM-based method in cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2007;30(Suppl 1):S19–22.PubMed
Metadata
Title
Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score
Authors
Z. Bakos
N. C. Chatterjee
C. Reitan
J. P. Singh
R. Borgquist
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0802-8

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue

Research article

The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease

Research article

Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) rs1558139, rs2108622 polymorphisms and susceptibility to several cardiovascular and cerebrovascular diseases

Research article

Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation

Research article

The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography

Research article

Independent association of resting energy expenditure with blood pressure: confirmation in populations of the African diaspora

Research article

Regional myocardial motion in patients with mild cognitive impairment: a pilot study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits